MedTrace Logo

Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients

NCT03784222 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2024-04-19

No results posted yet for this study

Summary

This is an open label, multi-center study to explore the effects on social functions of blonanserin in first episode schizophrenia patients

Conditions

  • First Episode Schizophrenia
  • Social Function
  • Cognition Function
  • Blonanserin

Interventions

DRUG

Blonanserin

patients were prescribed blonanserin 4-24mg/d according to the patients' response and tolerability

OTHER

MRI and serum BDNF

60 patients receive MRI and serum BDNF test, 60 controls receive MRI, 20 of the 60 controls receive serum BDNF test

Sponsors & Collaborators

  • Sumitomo Pharma (Suzhou) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xin Yu, MD · Peking University Sixth Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-22
Primary Completion
2022-11-22
Completion
2022-11-22

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03784222 on ClinicalTrials.gov